Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $17.5714.

Several analysts recently issued reports on IMRX shares. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Tuesday, May 19th. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Cantor Fitzgerald assumed coverage on shares of Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target for the company. Finally, Needham & Company LLC raised their price target on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th.

Immuneering Stock Down 1.6%

Shares of Immuneering stock opened at $4.32 on Friday. The stock has a market capitalization of $279.50 million, a P/E ratio of -3.69 and a beta of 0.41. The stock has a 50 day moving average price of $4.75 and a two-hundred day moving average price of $5.05. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. Sell-side analysts anticipate that Immuneering will post -1.09 earnings per share for the current year.

Institutional Trading of Immuneering

Several hedge funds have recently added to or reduced their stakes in IMRX. Geode Capital Management LLC grew its holdings in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Immuneering during the fourth quarter worth approximately $33,000. Southport Management L.L.C. lifted its holdings in shares of Immuneering by 1.8% during the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after buying an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after acquiring an additional 6,196 shares during the period. Finally, LPL Financial LLC grew its stake in shares of Immuneering by 30.0% in the fourth quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after acquiring an additional 6,725 shares during the last quarter. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.